Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $44.2 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2024 revenue of $200-220 million, versus the consensus of $219.1 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.